Henry Schein, Inc.

Equities

HSIC

US8064071025

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2025-12-10 pm EST			5-day change	1st Jan Change
75.88 ^USD	+1.93%		+4.12%	+9.65%

Dec. 09	Barclays Initiates Henry Schein With Overweight Rating, $86 Price Target	MT
Dec. 02	Henry Schein, Inc. Presents at Piper Sandler 37th Annual Healthcare Conference, Dec-02-2025 09:00 AM

Henry Schein, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 27, 2025

Published on 11/04/2025 at 08:53 am EST - Modified on 11/04/2025 at 06:00 am EST

S&P Capital IQ

Henry Schein, Inc.

+1.93%

Henry Schein, Inc. reported earnings results for the third quarter and nine months ended September 27, 2025. For the third quarter, the company reported sales was USD 3,339 million compared to USD 3,174 million a year ago. Sales was USD 3,339 million compared to USD 3,174 million a year ago. Net income was USD 101 million compared to USD 99 million a year ago. Net income was USD 101 million compared to USD 99 million a year ago. Basic earnings per share from continuing operations was USD 0.84 compared to USD 0.79 a year ago. Basic earnings per share from continuing operations was USD 0.84 compared to USD 0.79 a year ago. Diluted earnings per share from continuing operations was USD 0.84 compared to USD 0.78 a year ago. Diluted earnings per share from continuing operations was USD 0.84 compared to USD 0.78 a year ago.
For the nine months, sales was USD 9,747 million compared to USD 9,482 million a year ago. Sales was USD 9,747 million compared to USD 9,482 million a year ago. Net income was USD 297 million compared to USD 296 million a year ago. Net income was USD 297 million compared to USD 296 million a year ago. Basic earnings per share from continuing operations was USD 2.44 compared to USD 2.32 a year ago. Basic earnings per share from continuing operations was USD 2.44 compared to USD 2.32 a year ago. Diluted earnings per share from continuing operations was USD 2.42 compared to USD 2.3 a year ago. Diluted earnings per share from continuing operations was USD 2.42 compared to USD 2.3 a year ago.

Latest news about Henry Schein, Inc.

Dec. 09	Barclays Initiates Henry Schein With Overweight Rating, $86 Price Target	MT
Dec. 02	Henry Schein, Inc. Presents at Piper Sandler 37th Annual Healthcare Conference, Dec-02-2025 09:00 AM
Dec. 01	Henry Schein Becomes Exclusive US Distributor of vVARDIS' Curodont Treatment in January	MT
Dec. 01	Henry Schein, Inc. Expands Partnership with Vvardis	CI
Nov. 25	Biomerica's inFoods IBS Product Featured in Biotherapeutics Quarterly	CI
Nov. 18	Henry Schein, Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-18-2025 02:30 PM
Nov. 12	Henry Schein, Inc. Presents at Stifel 2025 Healthcare Conference, Nov-12-2025 11:20 AM
Nov. 05	VideaHealth and Henry Schein One Launch the Impact Panel, Bringing AI-Driven Patient Education to Dentrix and Dentrix Ascend	CI
Nov. 05	JPMorgan Adjusts Price Target on Henry Schein to $78 From $80, Maintains Overweight Rating	MT
Nov. 05	Morgan Stanley Adjusts Price Target on Henry Schein to $58 From $55, Maintains Underweight Rating	MT
Nov. 05	Baird Adjusts Price Target on Henry Schein to $78 From $72, Maintains Neutral Rating	MT
Nov. 05	Stifel Adjusts Price Target on Henry Schein to $72 From $70, Maintains Neutral Rating	MT
Nov. 05	Evercore ISI Adjusts Price Target on Henry Schein to $90 From $83, Maintains Outperform Rating	MT
Nov. 04	Tranche Update on Henry Schein, Inc.'s Equity Buyback Plan announced on December 13, 2018.	CI
Nov. 04	Wall St falls after big banks' CEOs warn of market downturn; Palantir slides	RE
Nov. 04	Henry Schein, Inc. Raises Earnings Guidance for the Year 2025	CI
Nov. 25	Henry Schein, Inc., Q3 2025 Earnings Call, Nov 04, 2025
Nov. 04	Henry Schein, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 27, 2025	CI
Nov. 04	Henry Schein lifts annual forecast on strong dental, medical equipment sales	RE
Nov. 04	MORNING BID AMERICAS-Nerves rising about frothy valuations	RE
Nov. 04	Nerves rising about frothy valuations	RE
Nov. 04	Henry Schein Q3 Adjusted Earnings, Revenue Rise; 2025 EPS Guidance Raised	MT
Nov. 04	(HSIC) Henry Schein Expects Full Year 2025 Adjusted EPS Range $4.88 to $4.96, vs. FactSet Est of $4.82	MT
Nov. 04	Henry Schein Q3 results beat estimates	RE
Nov. 04	Earnings Flash (HSIC) Henry Schein, Inc. Reports Q3 Revenue $3.34B, vs. FactSet Est of $3.28B	MT

Chart Henry Schein, Inc.

Duration

Period

HSIC: Dynamic Chart

Company Profile

Henry Schein, Inc. specializes in the distribution of care products and services intended for health professionals (doctors, surgeons, dentists, veterinary laboratories and clinics). Net sales break down by activity as follows: - distribution of health care products and equipment (83.8%): dental products and equipment (62.1% of net sales; consumable products, laboratory equipment, print materials, implants, anesthetics, etc.) and medical equipment (37.9%; medicines, vaccines, vitamins, surgical material, diagnostic tests, etc.); - other (16.2%): sale and integration of management software, financial, training, maintenance and equipment repair services. The United States account for 69.5% of net sales.

Employees

25,000

Sector

Medical Equipment, Supplies & Distribution

Calendar

Feb. 17 - Q4 2025 Earnings Release (Projected)

More about the company